Nicotinic Receptors and Schizophrenia

VA Office of Research and Development10 enrolled

Overview

The study determines if a new preparation of a drug designed to treat schizophrenia is more slowly released into the body.

3-2,4 dimethoxybenzylidene will be compounded with a methyallose compound in doses of 150 and 300 mg. The capsules will be administered singly and eventually bid to determine if sustained blood levels comparable to steady state blood levels seen in previous studies can be determined. Safety and EEG effects will be measured.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Schizophrenia

Interventions

PharmacokineticDRUG

Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy volunteers: males and females who are incapable of pregnancy Exclusion Criteria: * Medical illnesses requiring acute treatment * History of seizures * Substance abuse including nicotine

Locations (1)

VA Eastern Colorado Health Care System, Denver

Denver, Colorado, United States

Outcomes

Primary Outcomes

Blood Levels of Drug

This is the plasma level of the drug as determined by high performance liquid chromatography.

Time frame: 12 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.